PDF(Pubmed)
Abstract：
Obesity poses significant challenges, necessitating comprehensive strategies for effective intervention. Bariatric Surgery (BS) has emerged as a crucial therapeutic approach, demonstrating success in weight loss and comorbidity improvement. This study aimed to evaluate the outcomes of BS in a cohort of 48 Uruguayan patients and investigate the interplay between BS and clinical and metabolic features, with a specific focus on FSTL1, an emerging biomarker associated with obesity and inflammation. We quantitatively analyzed BS outcomes and constructed linear models to identify variables impacting BS success. The study revealed the effectiveness of BS in improving metabolic and clinical parameters. Importantly, variables correlating with BS success were identified, with higher pre-surgical FSTL1 levels associated with an increased effect of BS on BMI reduction. FSTL1 levels were measured from patient plasma using an ELISA kit pre-surgery and six months after. This research, despite limitations of a small sample size and limited follow-up time, contributes valuable insights into understanding and predicting the success of BS, highlighting the potential role of FSTL1 as a useful biomarker in obesity.
摘要：
肥胖带来了重大挑战，需要采取综合战略进行有效干预。减肥手术（BS）已经成为一种重要的治疗方法，证明在减肥和改善共病方面取得了成功。本研究旨在评估48名乌拉圭患者的BS结果，并调查BS与临床和代谢特征之间的相互作用。特别关注与肥胖和炎症相关的新兴生物标志物FSTL1。我们定量分析了BS结果，并构建了线性模型来确定影响BS成功的变量。该研究揭示了BS在改善代谢和临床参数方面的有效性。重要的是,确定了与BS成功相关的变量，术前FSTL1水平升高与BS对BMI降低的影响增加相关。手术前和6个月后使用ELISA试剂盒从患者血浆中测量FSTL1水平。这项研究,尽管样本量小和随访时间有限，有助于理解和预测BS的成功，强调FSTL1作为肥胖有用的生物标志物的潜在作用。
